Posts Tagged ‘Marissa Brassfield’


Wednesday, July 11th, 2018

Chiyo Miyako of Japan is the world’s oldest verified living person at 117 years, as of June 29, 2018, according to the Gerontology Research Group. She credits eating eel, drinking red wine, and never smoking for her longevity, and enjoys calligraphy. (credit: Medical Review Co., Ltd.)

What it is: An international team of scientists have come to the conclusion that there is no known limit to human lifespan. Published in the journal Science, the findings are based on a new set of high-quality data collected on Italians over the age of 105. While risk of death increases exponentially from age 65 to 80, the range of risk increases after 80 — meaning that risks are more varied person to person — and after age 105, overall risks seems to plateau at an average 50 percent of living another year.

Why it’s important: Even without the many advances we have made in recent years to save lives and extend healthy lifespans, this analysis suggests that mortality is not a foregone conclusion, as many might believe. Look for this to begin to turn public opinion, and for an increased acceptance of longevity research overall.

Abundance Insider:  Spotted by Marissa Brassfield / Written by Jason Goodwin 


Sunday, October 29th, 2017

The Food and Drug Administration recently approved a trial to use adipose-derived stem cells to treat non-healing leg ulcers, a common complication of diabetes, in a study conducted by researchers at Sanford Health.  “This clinical trial can help explore treatments for people with non-healing wounds, including people who have diabetes and others with conditions that affect their quality of life,” according to David Pearce, Ph.D., executive vice president of innovation and research at Sanford Health. According to the World Health Organization, in 2014 more than 422 million people have been living with diabetes globally.  The trials, which began in September, followed a similar study in which stem cells were tested for the treatment of shoulder injuries.

While the study has not yet been completed, the FDA’s support indicates growing interest in this arena.  According to Marissa Brassfield of Abundance 360, “this is a great example of how we can use exponential technology advances to tackle large-scale problems — like the 2 to 5 million people living with chronic wounds in the United States alone — which serves to fund a larger vision, refine the technical details, and explore adjacent applications.”